Abstract: Out of 100 patients with osteoarthritis (OA), almost 40 have a concomitant diagnosis of hypertension. Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors may trigger a rise in blood pressure (BP), which is more marked in patients with established hypertension. NSAIDs and COX-2 inhibitors attenuate the antihypertensive effect of several antihypertensive agents. Frequent BP controls are needed in treated hypertensive patients who are concomitantly receiving NSAIDs or COX-2 inhibitors because even a small increase in BP may be associated with an important rise in the risk of major cardiovascular complications. In meta-analyses, an increase in systolic BP of 5 mmHg was associated with a 25% higher risk of cardiovascular events. These data have been confirmed in randomized studies with rofecoxib and celecoxib, where a modest increase in BP was associated with a significantly higher risk of cardiovascular disease. There is emerging evidence that the COX-inhibiting nitric oxide donator (CINOD) class is promising in the treatment of patients with OA. Naproxcinod, the first CINOD investigated in clinical trials, is composed of the traditional NSAID naproxen covalently bound to the nitric oxide (NO)-donating moiety butanediol mononitrate (BDMN). The molecule has the potential to provide a sustained release of NO. In clinical studies, naproxcinod prevented the BP rise in normotensive and hypertensive patients observed with naproxen. The BP benefit of naproxcinod over naproxen was greater in patients concomitantly receiving angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. These investigational data suggest that naproxcinod is a valuable alternative to NSAIDs and COX-2 inhibitors for treatment of OA patients.
Introduction
Osteoarthritis (OA) is the most frequent musculoskeletal disease and the most frequent cause of pain and loss of functional and work ability [Woolf and Pfleger, 2003 ]. Owing to the progressive aging of the population and the growing burden of obesity, the incidence of OA is expected to consistently rise over the next decades. In addition to age and obesity, trauma and physically demanding occupations are additional determinants of the risk of OA, particularly at the level of hand, knee and hip [Lohmander et al. 2007] . OA imposes a significant financial burden both on patients and healthcare systems and it has been estimated that the cost of patients with OA is twice as much as that of patients without OA [Rabenda et al. 2006; Gabriel et al. 1997] .
OA and hypertension frequently coexist in the same patients [Singh et al. 2002] . The Third National Health and Nutrition Examination Survey (NHANES III) showed that OA is diagnosed in approximately 21% of the 115.9 million US adults aged !35 years that have OA [Singh et al. 2002] . NHANES III also estimated that a concomitant diagnosis of hypertension is present in 40% of these subjects [Singh et al. 2002] .
As shown in Figure 1 , other cardiovascular risk factors including diabetes, hypercholesterolemia and renal impairment are more frequent in patients with OA than in people without OA. Data in Figure 1 are derived from NHANES III [Singh et al. 2002] . Such a cluster of cardiovascular risk factors may be expected to affect the overall cardiovascular risk in these patients. Addressing this issue, Singh and colleagues estimated the potential impact on the risk of cardiovascular disease and the associated costs of treatment in relation with a given rise in systolic blood pressure (SBP) in patients with OA [Singh et al. 2003 ]. Estimates were based on patientlevel data from NHANES III in patients with OA and rheumatoid arthritis, and the Framingham equations for risk calculation. Using validated models, these authors estimated that increases in SBP of only 15 mmHg are associated with 710035,700 additional coronary artery disease and stroke events per year, with associated costs of between US$114 million and US$569 million [Singh et al. 2003 ]. The authors concluded that in cases where two different drugs for OA would have similar antiinflammatory efficacy but a different effect on systolic BP, considerations of incremental cardiovascular risk may become relevant [Singh et al. 2003 ].
Effects of non-steroidal anti-inflammatory drugs on blood pressure
The non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors are a diverse group of drugs that share an inhibitory effect on cyclooxygenase (COX), the rate-limiting enzyme which converts arachidonic acid to the labile intermediate PGH 2 . In turn, PGH 2 is converted to thromboxane A 2 by thromboxane synthase, prostacyclin by prostacyclin synthase and other prostaglandins including PGE 2 and PGD 2 . The metabolism of prostaglandins is markedly altered by COX inhibition.
Mechanisms of the blood pressure raising effect Although the exact mechanisms through which NSAIDs and COX-2 inhibitors may increase blood pressure (BP) levels are not completely known, experimental and clinical studies strongly suggest that these agents may trigger vasoconstriction and a marked antinatriuretic effect (Figure 2 ) [Simon et al. 2002; Morgan et al. 2000; Whelton, 2000; Brater, 1999] .
By inhibiting COX, NSAIDs systematically reduce the production of several prostaglandins with vasodilating effect, including PGE 2 and PGI 2 . At the renal level the inhibition of prostaglandins results in a drop in the renal blood flow, with reduced glomerular filtration rate and consequent rise in urea and creatinine [Whelton, 2000] . Inhibition of prostaglandins may also trigger an increase in chloride absorption, with consequent sodium retention, edema and hypertension. The reduction of prostaglandins may induce a reduction of renin and aldosterone, Therapeutic Advances in Musculoskeletal Disease 2 (4) with consequent potassium retention and hyperkalemia. Finally, the reduction in prostaglandins leads to an increase in the effect of antidiuretic hormone (ADH), which contributes to water retention with hyponatremia [Whelton, 2000] .
These adverse effects at a renal level are relatively rare in young and healthy people, in whom the kidneys are usually able to compensate for the effects of NSAIDs on sodium and water retention. Acute COX inhibition may reduce the urinary sodium excretion by 30% or more [Brater, 1999] . In the case of sustained COX inhibition in subjects with normal kidney function, a modest level of sodium and water retention, usually not accompanied by a rise in BP, is in most cases sufficient to re-increase sodium excretion, thereby preserving sodium and water hemostasis . This phenomenon may be impaired in patients with reduced kidney function, as well as in elderly people and in those with congestive heart failure (CHF), and this may result in considerable sodium and water retention, leading to a rise in BP in just a few weeks in these patients [Solomon et al. 2004; Whelton, 1999] . Fortunately, nephrotoxicity appears to be largely reversible after discontinuation of NSAIDs [Wilson and Poulter, 2006] .
In a study from the United Kingdom, the risk of CHF was about 60% higher on average in NSAID users than nonusers [Garcia Rodriguez and Hernandez-Diaz, 2003 ]. Among the different NSAIDs, the risk was highest for indomethacin and lowest for diclofenac [Garcia Rodriguez and Hernandez-Diaz, 2003 ].
Another mechanism for the rise in BP induced by NSAIDs and COX-2 inhibitors seems to be the inhibition of the synthesis of prostacyclin, which is known to exert a marked vasodilatory effect which counteracts the vasoconstriction triggered, for example, by angiotensin II and endothelin. Inhibition of prostacyclin may thus induce systemic vasoconstriction with rise in peripheral vascular resistance.
Effects in healthy subjects
The British Hypertension Society Guidelines have included NSAIDs as potential causes of BP elevation and deterioration of previously achieved BP control [Williams et al. 2004] . In general, normotensive and otherwise healthy subjects who need a short course of NSAIDs usually show only a minor and transient rise in BP [Kurth et al. 2005 ].
An analysis of a Medicare elderly population showed a rate of new-onset hypertension of 22% in subjects not treated with NSAIDs or COX-2 inhibitors. The rate of new-onset hypertension was not significantly different in subjects treated with celecoxib (21%) or NSAIDs (23%), but it rose significantly to 27% among subjects treated with rofecoxib [Solomon et al. 2004] . Subjects with concomitant kidney disease or CHF showed a systematically higher risk of developing new-onset hypertension [Solomon et al. 2004 ].
In the Nurses Health Study I, in which more than 51,000 nurses were followed for 8 years, the relative risk of developing hypertension progressively increased with the number of days per month of treatment with conventional NSAIDs [Dedier et al. 2002] . These data have been confirmed in the Nurses Health Study II, in which more than 80,000 nurses were followed for 2 years. The relative risk of developing hypertension also progressively increased with the number of days per month of treatment with conventional NSAIDs [Curhan et al. 2002] . In a pooled analysis of both Nurses Health Studies, the risk of developing hypertension also increased with the average daily dose of NSAIDs [Forman et al. 2005] . Notably, the same analysis removed the potential objection that headache may have confounded the relation between NSAID use and the rise in BP [Forman et al. 2005] .
Effects in hypertensive patients
Compared with healthy normotensive subjects, hypertensive patients subjected to long-term exposure to NSAIDs may experience a greater, although variable, degree of BP elevation. In individual studies, increases up to 10/7 mmHg [Morgan and Anderson, 1993] (systolic/diastolic BP) and 12/5 mmHg [Morgan et al. 2001] have been reported.
A meta-analysis by Pope and colleagues included 1324 subjects, 92% of whom were hypertensive, for a total of 54 studies. Overall, NSAIDs induced a rise in mean BP that averaged 3.3 mmHg in the hypertensive patients and only 1.1 mmHg in the normotensive subjects. In the hypertensive group, the rise in mean BP was 4.8 mmHg with indomethacin, 6.1 mmHg with naproxen and 2.9 mmHg with piroxicam. A limitation of this meta-analysis was the inclusion of generally healthy and young people, with exclusion of elderly subjects and patients with CHF, i.e. the subsets more frequently subjected to BP rises with NSAIDs [Pope et al. 1993] .
Another meta-analysis, carried out in 771 relatively young subjects (mean age 47.6 years) enrolled in 66 trials, showed a BP rise induced by NSAIDs of about 5.0 mmHg [Johnson et al. 1994] . Indomethacin, piroxicam and ibuprofen caused the greater rise in BP. Notably, NSAIDs antagonized the antihypertensive effects of beta blockers to a greater extent than that of vasodilators and diuretics [Johnson et al. 1994] .
There is general agreement that NSAIDs may attenuate the BP lowering effect of several antihypertensive agents, probably with the exclusion of calcium-channel blockers [Morgan et al. 2001; Polonia et al. 1995; Morgan and Anderson, 1993] . Whelton and colleagues reported the results of a comparative study between celecoxib and rofecoxib conducted in more than 1000 subjects with OA and hypertension who were concomitantly treated with fixed doses of antihypertensive drugs [Whelton et al. 2002] . In this study, rofecoxib induced a greater rise in BP compared with celecoxib, in patients treated with angiotensinconverting enzyme inhibitors (ACEIs) and beta blockers, but not in patients receiving calcium channel blockers [Whelton et al. 2002] .
A large study was the Therapeutic Arthritis Research and Gastrointestinal Event (TARGET) study, in which 18,325 patients with OA were randomized to lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg three times daily [Farkouh et al. 2004] . The primary cardiovascular endpoint, a composite of nonfatal and silent myocardial infarction, stroke, or cardiovascular death did not differ between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use. In this study, the patients randomized to lumiracoxib had a significantly smaller increase in SBP and diastolic BP from baseline values when compared with other NSAIDs including ibuprofen [Farkouh et al. 2004] .
Prognostic impact of blood pressure changes
There is general agreement that a direct, continuous and graded relationship exists between the Therapeutic Advances in Musculoskeletal Disease 2 (4) levels of BP and the risk of cardiovascular disease.
In a large meta-analysis of 61 observational studies, for a total of about 1 million individuals, a direct and linear relation was found between BP and mortality from coronary artery disease or stroke, beginning from values as low as 115/75 mmHg [Lewington et al. 2002] . Even more important, the relation was highly consistent across different age groups [Lewington et al. 2002] . Two limitations of this meta-analysis were the inclusion of generally uncomplicated subjects without prior cardiovascular disease, and the fact that BP was measured only in one single visit in each subject.
The prognostic impact of serial changes in BP was investigated in meta-regression analyses of intervention studies carried out in patients with high BP or increased cardiovascular risk. Again, a clear association was found between the degree of BP reduction and the size of the outcome benefit [Staessen et al. 2001] . For example, a 5 mmHg drop in BP was associated with a 25% reduction in the risk of major cardiovascular events [Staessen et al. 2005 ]. An interesting point was that the beneficial outcome associated with BP reduction appeared to be quite rapid to occur. This aspect emerged in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study. In this study, SBP was 3.8 mmHg lower in the amlodipine group compared with the valsartan group during the first 3 months of the trial [Julius et al. 2004] . This small BP difference between the groups was associated with a significantly lower incidence of cardiovascular events in the amlodipine group than in the valsartan group [Julius et al. 2004] . Over the following months the difference between the two groups in SBP progressively disappeared and the outcome differences between the two groups also disappeared [Julius et al. 2004] .
We have recently concluded the Studio Italiano Sugli Effetti Cardiovascolari del Controllo della Pressione Arteriosa Sistolica (Cardio-Sis) trial, in which 1111 treated nondiabetic patients with SBP !150 mmHg were randomly allocated to a goal SBP of <140 mmHg (usual control) or <130 mmHg (tight control) [Verdecchia et al. 2009] . Open-label agents were used to reach the randomized BP goals. The primary study endpoint was the proportion of patients with new development or lack of regression of electrocardiographic left ventricular hypertrophy 2 years after randomization and the main secondary endpoint was a composite pool of prespecified cardiovascular events and death. Over a median follow up of 2.0 years, the achieved BP was lower by 3.8/1.5 mmHg in the tight control group than in the usual control group. The primary endpoint of the study occurred less frequently in the tight than in the usual control group (p ¼ 0.013). Also the secondary endpoint occurred less frequently in the tight than in the usual control group (p ¼ 0.003).
These results suggest that, on a population basis, modest differences in BP are associated with a lesser risk of major clinical events even after a relatively short period. However, the clinical impact of small changes in BP in individual subjects is difficult to ascertain. BP measured in the physician's office may be biased for several reasons including the inherent errors in BP measurement and the alerting reaction to visit [Mancia et al. 1983] . Twenty-four-hour ambulatory BP provides a more reliable BP assessment [Verdecchia, 2000] 
Studies with NSAIDs and COX-2 inhibitors
Randomized intervention trials of NSAIDs or COX-2 inhibitors showed a clear-cut relation between small changes in BP and increased risk of major cardiovascular events. In the VIGOR study, where SBP increased by only 1.6 mmHg with naproxen and by 4.6 mmHg with rofecoxib, rofecoxib was associated with a 2.38 times higher risk of serious cardiovascular events [White, 2007; Bombardier et al. 2000] .
The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial was a comparative trial between rofecoxib and placebo in 2586 patients with a history of colorectal adenomas. In this study SBP increased by 3.4 mmHg with rofecoxib and decreased by 0.5 mmHg with placebo, while the risk of major cardiovascular events was 1.92 times higher with rofecoxib than with placebo (p ¼ 0.008) [Bresalier et al. 2005] .
Similar results were found in trials with celecoxib. In a nonprespecified post-hoc analysis of individual patient data from two celecoxib trials, the Adenoma Prevention with Celecoxib (APC) trial and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial, Solomon and colleagues found a direct association between the rise in SBP, which was of the order of 25 mmHg, and the incidence of adjudicated cardiovascular endpoints [Solomon et al. 2006] .
A concern on the potential implications of BP rise induced by traditional NSAIDs or COX-2 inhibitors has been expressed in a recent American Heart Association Scientific Statement, which suggested that BP and renal function should be monitored in subjects taking NSAIDs or COX-2 inhibitors [Antman et al. 2007] . This is especially relevant when these drugs are administered to patients with coexisting hypertension, renal disease and heart failure [Antman et al. 2007 ].
COX-inhibiting nitric oxide donor class
The COX-inhibiting nitric oxide donator (CINOD) class has been developed for the treatment of patients with osteoarthritis with the aim of an increased cardiovascular and gastrointestinal safety profile over NSAIDs. The underlying concept is that the nitric oxide (NO) released by these drugs would produce the mentioned beneficial effects [Fiorucci, 2009; Fiorucci et al. 2007; Wallace et al. 2002 Wallace et al. , 2009 . NO would also enhance the blood flow in the gastric mucosa, with consequent increased mucous production, reduced healing time and final effect of gastroprotection [Fiorucci, 2009] .
Several aspects regarding the pharmacokinetics of CINODs remain to be fully elucidated. In particular, it is unclear whether CINODs are cleaved before intestinal absorption, or whether they are absorbed intact and subsequently metabolized, possibly in the liver. The exact mechanisms of NO release also require further investigation. In particular, CINODs are able to release NO in biological fluids, not in inert media [Fiorucci, 2009] , and this raises the possibility that biological enzymes can intervene in the process of NO release in vivo.
Aspirin, naproxen, diclofenac and flurbiprofen have so far been coupled to a NO-releasing moiety [Fiorucci, 2009] . Naproxcinod, the first CINOD to be studied in large clinical trials, is composed of the traditional NSAID naproxen covalently bound to the NOdonating moiety butanediol mononitrate (BDMN) [Schnitzer et al. 2005] . Figure 3 shows the molecular structure of naproxen and naproxcinod. The molecule of naproxcinod is broken to produce naproxen and the NO-donating moiety. Plasma bioavailability of naproxen is reduced by about 1520% after administration of naproxcinod in comparison with equimolar doses of naproxen [Fagerholm and Bjornsson, 2005] and the gastrointestinal uptake of naproxen is also slower [Wallace et al. 2009] . After cleavage, the naproxen component of naproxcinod maintains its inhibitory activity on COX-1 and COX-2 while NO, released from the moiety is expected to exert its favorable biologic effects on the cardiovascular system. It is well established that NO produced by endothelial cells is capable to induce vasodilatation, inhibition of platelet aggregation and inhibition of vascular smooth muscle proliferation [Moncada and Higgs, 2006; Rees et al. 1989] (Figure 4 ). In the gastrointestinal mucosa, NO may trigger an increased blood flow with enhanced mucous production, thereby contributing to preserve gastric mucosal integrity [Wallace, 1996] . Naproxcinod is currently in a late stage of phase III clinical trials. A new drug application has been submitted to the US Food and Drug Administration in September 2009, and a marketing authorization application to the European Medicines Agency in December 2009.
Animal models
In animal models of OA, naproxcinod showed a similar efficacy to naproxen [Wallace et al. 2009] . Investigations in rodents showed a dose-related inhibition of COX-1 after both single and repeated administration [Muscara et al. 2000a] . 
Naproxcinod [4-(nitrooxy) butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate]
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Most likely as a result of the sustained NO release, naproxcinod reduced BP in spontaneously hypertensive rats and rats made hypertensive by L-NAME [Muscara et al. 1998 ] and protected isolated hearts of rabbits in ischemia-reperfusion models [Rossoni et al. 2004] . In a rat model of hypertension induced by partial occlusion of a renal artery (two-kidney, one-clip renovascular hypertension), naproxcinod significantly reduced BP when compared with both naproxen and vehicle [Muscara et al. 2000b] .
A convincing evidence that naproxcinod effectively releases NO in vivo came from studies in which a dose response was observed between the dose of naproxcinod and the circulating levels of NO [Rossoni et al. 2006] . As expected, naproxen did not cause any change in NO [Rossoni et al. 2006] . Another supporting evidence came from a study which showed a progressive increase in the levels of the second messenger cGMP, the specific signaling pathway of NO, with progressively higher doses of naproxcinod [Berndt et al. 2004] .
In animal experiments, naproxcinod caused less gastrointestinal damage when compared with equimolar doses of naproxen [Davies et al. 1997; Muscara et al. 1998 ]. In a human study, it improved gastrointestinal tolerability and induced fewer gastroduodenal erosions when compared with naproxen [Hawkey et al. 2003 ]. In a model of arthritic rats, naproxcinod reduced the degree of injury of gastric mucosa by approximately 70% when compared with equimolar doses of naproxen [Fiorucci et al. 2004] .
Effects on OA In a series of randomized, double-blind, placebocontrolled studies conducted in patients with OA on different sites, naproxcinod showed a similar potency to equimolar doses of naproxen [Karlsson et al. 2009; Lohmander et al. 2005; Schnitzer et al. 2005] . The dose of naproxcinod 750 mg twice daily showed the best balance between efficacy and safety [Karlsson et al. 2009] .
Gastroprotection in clinical studies
The solid evidence of gastroprotection that emerged from animal studies was partly confirmed in human investigations. In a study conducted in 31 healthy volunteers, the number of gastroduodenal erosions was 11.5 with naproxen and only 4.1 with naproxcinod (p < 0.01) [Hawkey et al. 2003 ]. In a multicenter study, naproxcinod significantly decreased the numbers of ulcers and erosions in stomach and stomach/ duodenum combined when compared with naproxen [Lohmander et al. 2005] . However, the incidence of ulcers !3 mm, the primary endpoint of the study, was 9.7% with naproxcinod and 13.7% with naproxen (p ¼ 0.07), versus 0% with placebo. The incidence of a Lanza score >2, an overall measure of gastroduodenal damage and secondary endpoint of the study, was significantly higher with naproxen than with naproxcinod (43.7% versus 32.2%; p < 0.001) [Lohmander et al. 2005] . 
BP in clinical studies
White and colleagues have recently published the results of a large clinical study in which 916 patients with OA of the knee were randomized to naproxcinod 375 mg and 750 mg twice daily, naproxen 500 mg twice daily or placebo. Duration of follow-up was 13 weeks. SBP decreased from baseline to week 13 by 2.9 mmHg more with naproxcinod than with naproxen (95% confidence interval À5.2 to À0.6; p ¼ 0.015) ( Figure 5 ). Furthermore, SBP decreased 0.8 mmHg more with naproxcinod than with placebo (95% confidence interval À3.3 to 1.6; p ¼ 0.505) [White et al. 2009] . A subset of 207 patients with OA and hypertension were concomitantly treated with ACEIs or angiotensin II receptor blockers (ARBs) alone or with diuretics. In these subjects, there was an average difference in SBP of 6.5 mmHg in favor of naproxcinod 750 mg over naproxen 500 mg (Figure 6 ). The proportion of patients with a SBP rise >10 mmHg was 22% with naproxen 500 mg and 14% with naproxcinod 750 mg (22% versus 14%; p ¼ 0.04) [White et al. 2009] . Overall, in this study naproxcinod eliminated the rise in SBP seen with naproxen and showed a similar effect on BP to that of placebo.
Clinical studies with 24-hour ambulatory BP In a randomized, double-blind, crossover study, 121 hypertensive subjects who were naïve to NSAIDs and COX-2 inhibitors received In another study, 118 patients with OA of hip or knee and controlled essential hypertension were randomized to naproxcinod 375 mg bid or naproxen 250 mg bid. Treatment was force titrated to the next highest dose at 3-week intervals (naproxcinod 750 and 1125 mg bid; naproxen 500 and 750 mg bid). Twenty-fourhour ambulatory BP monitoring was performed at baseline and at the end of each period. Naproxcinod resulted in persistently lower levels of 24-hour SBP, the primary endpoint of the study. In an intention-to-treat analysis, the overall difference between the treatments in the mean change in the average 24-hour SBP was 3.8 mmHg (SE 1.47) in favor of naproxcinod (p ¼ 0.011) [Townsend et al. 2009 ].
These findings indicate that naproxcinod does not display the profile of a traditional antihypertensive drug, but that of a NSAID provided with the remarkable safety feature of releasing NO, thereby avoiding the increase in BP commonly seen with NSAIDs.
Conclusion
Hypertension and other cardiovascular risk factors are common among patients with OA. In particular, the prevalence of hypertension is about 40%. Even modest increases in BP in these patients, in the order of those induced by traditional NSAIDs and COX-2 inhibitors, may significantly increase the risk of major cardiovascular complications and death. NSAIDs and COX-2 inhibitors may destabilize BP control by reducing the BP lowering effect of some antihypertensive agents including the ACEIs, the ARBs and the beta blockers. The CINOD class is being developed as an alternative to traditional NSAIDs and COX-2 inhibitors in order to combine the cyclooxygenase-mediated anti-inflammatory activity of the NSAID component with the systemic vasodilatation and potential gastrointestinal protection induced by the NO component. Naproxcinod, the first CINOD to be investigated in clinical trials, showed a similar effect to placebo on BP and less of an effect when compared with equimolar doses of naproxen in patients with OA.
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